|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
News and Press
  |
|
|
 |
|
OKTO’s state-of-the-art, multi-media exhibit displayed its core technologies for eye surgery: AmbioDry™ Amniotic Membrane Allografts and SutureGroove™ Gold Eyelid Weight Implants AmbioDry Allografts, processed tissue grafts derived from human placenta, are employed by eye surgeons for the treatment of a variety of ocular surface disorders and defects. AmbioDry Allografts are processed in the United States in alliance with Celgene Corporation. In comparison to competitive tissue options, the advantages of the AmbioDry are vast: decellularized, sterile tissue matrix; shelf-life storage; prepares in minutes for surgery; substrate-free; consistent tissue quality. SutureGroove Gold Eyelid Weights are employed by oculoplastic surgeons for the treatment of lagophthalmos. The proprietary SutureGroove technology, licensed by OKTO from AMI, incorporates suture fixation channels within the gold weight for perfected implant placement and improved patient cosmesis. “We are extremely excited with and pleased by the enthusiastic reception both the AmbioDry and SutureGroove technologies received at this critical meeting. We are further rewarded with the assurance that we are offering the ophthalmologist clear benefits in safety, logistics and ease of use”, stated Erich Ziegler President of OKTO Ophtho. About OKTO Founded in 2000, OKTO Ophtho develops and commercializes specialized, leading-edge surgical technologies for eye surgery. OKTO’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider. OKTO currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for ocular surface/ophthalmic reconstructive Media Contact: |
 |